People on the Move
reViral
Antiviral drug discovery and development company reViral, which focuses on diseases caused by the respiratory syncytial virus (RSV), has appointed Raymond Schinazi to its board as a non-executive director.
Schinazi is the founder of several biotechnology companies, including Pharmasset, where he directed the research that led to the discovery of Sovaldi, a therapy for hepatitis C infections later developed by Gilead Sciences.
ReViral’s lead compound, RV521, is an orally bioavailable antiviral inhibitor targeting RSV fusion. RSV is the cause of up to 200,000 deaths annually in children under 5 years and currently has no available vaccine.